Wave Life Sciences (WVE) EBITDA Margin (2015 - 2026)

Wave Life Sciences (WVE) has 12 years of EBITDA Margin data on file, last reported at 3248.33% in Q2 2026.

• Quarterly EBITDA Margin fell 264183.0% year-over-year to 3248.33% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 373.2% (down 8678.0% YoY) and the FY2025 annual result came in at 504.09%, down 40215.0% from the prior year.
• EBITDA Margin eased to 3248.33% in Q2 2026, from 81.83% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 9.03% in Q3 2023 to a low of 13648.77% in Q3 2022.
• A 5-year average of 2565.21% and a median of 408.83% in 2025 frame the typical range for EBITDA Margin.
• Annual changes were most pronounced in 2022 — EBITDA Margin sank 1362789 bps — and 2023, when it surged 1365780 bps.
• Tracing WVE's EBITDA Margin over 5 years: stood at 3515.98% in 2022, then jumped by 98 bps to 64.3% in 2023, then slumped by 176 bps to 177.72% in 2024, then plunged by 241 bps to 606.49% in 2025, then plunged by 436 bps to 3248.33% in 2026.
• The last three EBITDA Margin figures came in at 3248.33% (Q2 2026), 81.83% (Q1 2026), and 606.49% (Q2 2025), per Business Quant data.